A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

NCT01631487 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-39439335 10 mg
DRUG: JNJ-39439335 25 mg
DRUG: JNJ-39439335 50 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC